Details:
CAMYO-01 is a novel off-the-shelf cancer vaccine, which is incorporates a pool of colorectal cancer-specific camyotopes formulated into an mRNA-based vaccine.
Lead Product(s): CAMYO-01
Therapeutic Area: Oncology Product Name: CAMYO-01
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2023
Details:
The proceeds will fund the research and development expenses, to advance its preclinical B7-H6 specific CAR T-cell candidates, to discover and develop additional preclinical product candidates using its proprietary non-gene edited short hairpin RNA technology platform.
Lead Product(s): B7-H6 Specific CAR T-cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Fortress Investment Group
Deal Size: $10.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 24, 2023
Details:
Under the agreement, Ardena will provide additional Good Manufacturing Practice (cGMP)-standard manufacturing capability for Race’s flagship intravenous (IV) formulation of RC220 (bisantrene dihydrochloride).
Lead Product(s): Bisantrene
Therapeutic Area: Oncology Product Name: RC220
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Race Oncology
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Agreement July 12, 2023
Details:
The transaction gives Kiniciti a control stake in Ncardia to support growth and enhance capabilities spanning discovery to clinical programs to manufacturing of human-induced pluripotent stem cell-based solutions (iPSC).
Lead Product(s): iPSC-based Allogenic Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Kiniciti
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Partnership November 15, 2021
Details:
The proof-of-concept study showed the potential of Cell-Penetrating Alphabodies to efficiently penetrate the cancer cell membrane, disrupt an intracellular protein-protein interface, and cause an anti-tumor effect upon in vivo administration in relevant xenograft models.
Lead Product(s): Cell-Penetrating Alphabodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2021
Details:
Under the terms of the agreement, Complix will use its proprietary Alphabody platform to deliver Cell Penetrating Alphabodies (CPABs) against two immuno-oncology intracellular targets.
Lead Product(s): Cell penetrating alphabodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: I-Mab Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 10, 2021